PTC Therapeutics (PTCT) said Wednesday that a new drug application for vatiquinone for the treatment of adults and children with Friedrich's ataxia has been accepted by the U.S. Food and Drug Administration for priority review.
The agency has set Aug. 19 as the target action date for the drug under the Prescription Drug User Fee Act.
Data from three studies showed that vatiquinone demonstrated "significant" evidence of slowing disease progression with regard to key aspects of the neuromuscular disease, the company said.
Shares were 3.3% higher in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。